Actions
Pages
Subscribe for newsletter
Stories
Genesis Therapeutics harnesses AI in a landmark $200 million funding round, highlighting a pivotal moment for AI-enabled drug development and the biotech sector's rapid growth.
The substantial investment in Genesis underscores a broader confidence in AI's role in pioneering advanced drug discovery and development, signaling a potential shift in traditional biotech strategies. This evolution is not just theoretical; it's now entering a practical, critical stage with real-world impacts.
"AI presents a potent opportunity to revolutionize the drug discovery process," said CEO Dr. Evan Feinberg. "This funding comes as Genesis is approaching an inflection point with the first of our AI-enabled drug candidates entering the clinic."
The industry anticipates the forthcoming clinical trials of Genesis' AI-enabled drug candidates, marking a significant milestone in AI's practical application in biotech. Success here could catalyze a larger shift toward technology-driven approaches in the sector.
This development is part of a larger trend. Companies like Mana.bio are also merging AI with biotech for drug development, emphasizing the growing importance of technology in this field. Despite external challenges, such as recent attacks in Israel impacting Mana.bio’s operations, these companies remain steadfast in their missions, showing the resilience and urgency of innovation in this space.
Biotech & Artificial Intelligence
Story
While lithium-ion batteries have made impressive strides, a tech startup believes there's untapped potential in existing designs. Breathe Battery Technologies is breathing new life into lithium-ion batteries with cutting-edge software that promises faster charging times and enhanced longevity.
Lithium-ion batteries have become the lifeblood of the rapidly growing electric vehicle (EV) market, constituting 60% of the world's battery production, with no signs of slowing down. Breathe's innovation can reshape the EV landscape by making batteries more efficient and sustainable.
Ian Campbell, Co-founder and CEO at Breathe, states, "Customers get a better, longer-lasting laptop or car. If you're the OEM that sells it to us, you have a more sustainable product, you have better warrantability, you have less balance sheet risk."
The automotive sector is set to be the focal point of Breathe's endeavors. With electric vehicles on the rise, lithium-ion batteries are in high demand. Breathe's software promises to further transform the EV market by making these vehicles more efficient, sustainable, and cost-effective. Conversations with car manufacturers are already in advanced stages, with tremendous excitement in the automotive industry.
Breathe's software operates on industry-standard microcontrollers, ensuring broad compatibility in electric vehicles and electronic devices. This innovation aligns with the global trend toward more sustainable transportation solutions and cleaner energy practices.
Emerging Technology in Battery Optimization
Breathe Battery Technologies' pioneering software is set to redefine the lithium-ion battery industry, offering a brighter and more sustainable future for electronic devices and electric vehicles alike. As the automotive sector continues to expand, Breathe's innovations are poised to play a pivotal role in shaping the industry's future.
Story
In a world where environmental sustainability and the food industry are inextricably linked, Lyon, France-based startup Bon Vivant is making waves with precision fermentation technology. Their innovative approach to crafting animal-free dairy proteins has the potential to revolutionize the agri-food market and meet the growing demand for animal proteins while minimizing environmental impact.
As the global demand for animal proteins is projected to increase by 50-100% by 2050, the dairy industry faces a unique set of challenges. Conventional milk production is declining, and the existing agricultural model is a major contributor to climate change. Bon Vivant's precision fermentation technology represents a sustainable alternative to traditional dairy production. By producing milk proteins through fermentation, they can offer an eco-friendly solution that meets the world's rising appetite for animal-free dairy.
Stéphane MacMillan, CEO and founder of Bon Vivant, notes, "We are very proud of this new stage in the development of Bon Vivant, which enables us to welcome leading investors from the biotechnology and agri-food industries to our capital. This round of financing confirms the growing demand for precision fermentation as a solution to the tremendous challenges the agri-food industry, particularly the dairy industry, is facing."
Bon Vivant's precision fermentation technology is well-positioned to address the challenges of the dairy industry. They plan to continue scaling production, obtaining necessary regulatory approvals, and preparing for commercialization by 2025, particularly in the United States. Their unique model and technology could help the industry reduce its carbon footprint and meet the growing demand for dairy proteins.
Precision fermentation is not just about replicating existing molecules more sustainably but also introducing entirely new ones with the same sensory benefits. This technology holds the potential to disrupt markets, from natural food colorings to artificial additives.
Emerging Agri-Tech and FoodTech
The precision fermentation sector, particularly in animal-free dairy proteins, is gaining momentum, with Bon Vivant at the forefront of innovation. Their success story highlights the potential for a more sustainable agri-food era where technology meets the world's growing protein demands while respecting our planet.
Story
Innovators
Scroll
Open
Close